Inqovi

Chemical Namedecitabine and cedazuridine
Dosage FormTablets; (oral; 35 mg decitabine and 100 mg cedazuridine)
Drug ClassMiscellaneous
SystemBlood
CompanyOtsuka Pharmaceutical Co.
Approval Year2020

Indication

  • For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS.
Last updated on 12/7/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inqovi (decitabine and cedazuridine) Prescribing Information.2020Otsuka Pharmaceutical Co., Japan